File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Therapeutic potential of neurogenesis and melatonin regulation in Alzheimer’s disease

TitleTherapeutic potential of neurogenesis and melatonin regulation in Alzheimer’s disease
Authors
KeywordsAlzheimer's disease
neurogenesis
melatonin
preclinical
Issue Date2020
PublisherWiley-Blackwell Publishing, Inc. The Journal's web site is located at http://www.blackwellpublishing.com/journal.asp?ref=0077-8923&site=1
Citation
Annals of the New York Academy of Sciences, 2020, Epub 2020-07-22 How to Cite?
AbstractAlzheimer’s disease (AD) is an age-related neurodegenerative disorder characterized by hallmark pathologies of amyloid-beta plaques and neurofibrillary tangles. Symptoms of this devastating disease include behavioural changes and deterioration of higher cognitive functions. Impairment of neurogenesis has also been shown to occur in AD, which adversely impacts new neuronal cell growth, differentiation, and survival. This impairment possibly results from the cumulative effects of the various pathologies of AD. Preclinical studies have suggested that the administration of melatonin, the pineal hormone primarily responsible for the regulation of the circadian rhythm, targets the effects of AD pathologies and improves cognitive impairment. It is postulated that by mitigating the effect of these pathologies, melatonin can also rescue neurogenesis impairment. This review aims to explore the effect of AD pathologies on neurogenesis, as well as the mechanisms by which melatonin is able to ameliorate AD pathologies to potentially promote neurogenesis.
Persistent Identifierhttp://hdl.handle.net/10722/284514
ISSN
2019 Impact Factor: 4.728
2015 SCImago Journal Rankings: 2.389
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorMihardja, M-
dc.contributor.authorROY, J-
dc.contributor.authorWong, KY-
dc.contributor.authorAquili, L-
dc.contributor.authorHeng, BC-
dc.contributor.authorChan, YS-
dc.contributor.authorFung, M-
dc.contributor.authorLim, LW-
dc.date.accessioned2020-08-07T08:58:44Z-
dc.date.available2020-08-07T08:58:44Z-
dc.date.issued2020-
dc.identifier.citationAnnals of the New York Academy of Sciences, 2020, Epub 2020-07-22-
dc.identifier.issn0077-8923-
dc.identifier.urihttp://hdl.handle.net/10722/284514-
dc.description.abstractAlzheimer’s disease (AD) is an age-related neurodegenerative disorder characterized by hallmark pathologies of amyloid-beta plaques and neurofibrillary tangles. Symptoms of this devastating disease include behavioural changes and deterioration of higher cognitive functions. Impairment of neurogenesis has also been shown to occur in AD, which adversely impacts new neuronal cell growth, differentiation, and survival. This impairment possibly results from the cumulative effects of the various pathologies of AD. Preclinical studies have suggested that the administration of melatonin, the pineal hormone primarily responsible for the regulation of the circadian rhythm, targets the effects of AD pathologies and improves cognitive impairment. It is postulated that by mitigating the effect of these pathologies, melatonin can also rescue neurogenesis impairment. This review aims to explore the effect of AD pathologies on neurogenesis, as well as the mechanisms by which melatonin is able to ameliorate AD pathologies to potentially promote neurogenesis.-
dc.languageeng-
dc.publisherWiley-Blackwell Publishing, Inc. The Journal's web site is located at http://www.blackwellpublishing.com/journal.asp?ref=0077-8923&site=1-
dc.relation.ispartofAnnals of the New York Academy of Sciences-
dc.rightsPreprint This is the pre-peer reviewed version of the following article: [FULL CITE], which has been published in final form at [Link to final article using the DOI]. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions. Postprint This is the peer reviewed version of the following article: [FULL CITE], which has been published in final form at [Link to final article using the DOI]. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions.-
dc.subjectAlzheimer's disease-
dc.subjectneurogenesis-
dc.subjectmelatonin-
dc.subjectpreclinical-
dc.titleTherapeutic potential of neurogenesis and melatonin regulation in Alzheimer’s disease-
dc.typeArticle-
dc.identifier.emailChan, YS: yschan@hku.hk-
dc.identifier.emailFung, M: fungml@hku.hk-
dc.identifier.emailLim, LW: limlw@hku.hk-
dc.identifier.authorityChan, YS=rp00318-
dc.identifier.authorityFung, M=rp00433-
dc.identifier.authorityLim, LW=rp02088-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1111/nyas.14436-
dc.identifier.pmid32700392-
dc.identifier.hkuros311495-
dc.identifier.volumeEpub 2020-07-22-
dc.identifier.isiWOS:000551037600001-
dc.publisher.placeUnited States-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats